Recent Investment Analysts’ Ratings Updates for Design Therapeutics (DSGN)

by · The Markets Daily

Design Therapeutics (NASDAQ: DSGN) has recently received a number of price target changes and ratings updates:

  • 12/6/2025 – Design Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
  • 12/3/2025 – Design Therapeutics is now covered by analysts at Craig Hallum. They set a “buy” rating and a $15.00 price target on the stock.
  • 12/3/2025 – Design Therapeutics was given a new $14.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
  • 12/3/2025 – Design Therapeutics is now covered by analysts at Craig Hallum. They set a “buy” rating on the stock.
  • 12/3/2025 – Design Therapeutics was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
  • 11/20/2025 – Design Therapeutics was upgraded by analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating. They now have a $13.00 price target on the stock, up previously from $6.00.
  • 11/8/2025 – Design Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
  • 11/6/2025 – Design Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $6.00. They now have a “sector perform” rating on the stock.

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Further Reading